Virtus LifeSci Biotech Clinical Trials ETF BBC has shed 22%. Virtus LifeSci Biotech Clinical Trials ETF (BBC): ETF Research Reports While inflationary pressures, tightening policies from the central banks worldwide and geopolitical issues are making investors jittery, an improving economy, rising consumer confidence and solid corporate earnings are acting as catalysts.